Market research
N4P.LSE N4 Pharma Plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- Not available
- Beta
- 0.29
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BYW8QM32
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- Not available
- Beta
- 0.29
About
About N4 Pharma Plc
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the N4P.LSE discussion.
5 years, 4 months ago
N4 Pharma Plc is currently in a long term uptrend where the price is trading 13.2% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has dropped by 0.0% to $-162K since the same quarter in the previous year.
Finally, its free cash flow fell by 421.6% to $-475K since the same quarter in the previous year.
Based on the above factors, N4 Pharma Plc gets an overall score of 2/5.